Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients
about
HCV Kinetic Models and Their Implications in Drug DevelopmentModelling hepatitis C therapy--predicting effects of treatmentA Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyImprovement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
P2860
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@ast
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@en
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@nl
type
label
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@ast
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@en
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@nl
prefLabel
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@ast
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@en
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@nl
P2093
P2860
P50
P356
P1476
Using pharmacokinetic and vira ...... us-infected cirrhotic patients
@en
P2093
Christophe Hézode
Cédric Laouénan
Céline Dorival
Fabien Zoulim
Feryel Khelifa-Mouri
Florence Nicot
France Mentré
Jean-Pierre Bronowicki
Lawrence Serfaty
Martine Lapalus
P2860
P304
P356
10.1128/AAC.02611-14
P407
P577
2014-06-30T00:00:00Z